Abstract
There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Annals of oncology : official journal of the European Society for Medical Oncology / ESMO |
Vol/bind | 24 |
Udgave nummer | 10 |
Sider (fra-til) | 2554-9 |
Antal sider | 6 |
ISSN | 0923-7534 |
DOI | |
Status | Udgivet - okt. 2013 |